BioCentury
ARTICLE | Clinical News

Optune survival readout boosts Novocure

September 12, 2016 7:00 AM UTC

Novocure Ltd. (NASDAQ:NVCR) gained $0.53 to $8.62 on Monday after it said a long-term analysis of a Phase III study showed Optune ( NovoTTF-100A) significantly improved survival after four years in patients with newly diagnosed glioblastoma multiforme.

The 695-patient EF-14 study evaluated Optune alone or in combination with temozolomide. The company said it will present the analysis at next month's Society for Neuro-Oncology meeting in Scottsdale, Arizona. ...